Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple-dose study of AZD7503 in healthy Japanese participants
jRCT2071230075Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing AZD7503 with Placebo (2 arms). Primary endpoints: Safety and tolerability of AZD7503, Cardiac safety (ECGs and telemetry) and 4 more. Started Oct 2023; status: completed.
02
Drugs
AZD7503
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCT2071230075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230075.